Generated by AI
60 Degrees Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for the prevention and treatment of infectious diseases. Its commercial portfolio centers on Arakoda, a malaria prevention therapy, while its broader pipeline includes tafenoquine-based programs and other candidates being studied for vector-borne, fungal, and viral infections. The company works across areas such as malaria, babesiosis, respiratory infections, and dengue, reflecting a research strategy aimed at diseases with significant unmet medical need. 60 Degrees Pharmaceuticals Inc. serves as a niche biotechnology player in the healthcare market, combining product commercialization with ongoing clinical development. Headquartered in Washington, D.C., the company also maintains operations linked to research and collaboration in Australia.
Website1025 Connecticut Avenue NW
Washington, DC, 20036
United States
The latest articles about SXTP.
Tipranks Press Release.
Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, today announced expansion of its vector-borne disease research portfolio through a sponsored research agreement with The University of Southern Mississippi (USM) to assess the therapeu
Summary of Oct 28's posts. Generated by AI.
Summary of Oct 27's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about SXTP also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.